STOCK TITAN

[Form 4] Camp4 Therapeutics Corp Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Andrew J. Schwab, a director and 10% owner of Camp4 Therapeutics Corp (CAMP), reported an acquisition on Form 4. The filing shows a transaction dated 09/11/2025 in which 2,941,176 shares of common stock were acquired at $1.53 per share. The shares are reported as indirectly owned through 5AM Ventures VII, L.P. The filing also discloses additional indirect holdings attributed to related 5AM entities: 2,625,145 shares held by 5AM Ventures VI, L.P. and 302,770 shares held by 5AM Opportunities II, L.P. Explanatory footnotes state Schwab is a managing member of the general partner entities and disclaims direct beneficial ownership except to the extent of pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Significant indirect acquisition reported: 2,941,176 shares purchased at $1.53, ownership held via 5AM Ventures VII.

The Form 4 documents a material non-derivative acquisition by entities associated with Andrew J. Schwab on 09/11/2025. The reported price of $1.53 per share for 2,941,176 shares is explicit and sizable for a single transaction. The filing clarifies the position is held indirectly through 5AM Ventures VII, with additional indirect stakes disclosed in affiliated 5AM vehicles. This indicates consolidated exposure from Schwab-affiliated funds rather than a personal, direct stake; the footnotes properly disclose the governance relationship and disclaimer of direct beneficial ownership.

TL;DR: Governance disclosure shows indirect holdings via venture fund structures with standard disclaimers of direct ownership.

The statement of changes in beneficial ownership follows Section 16 formatting and includes explanatory notes identifying the general partner entities and Schwab's role as a managing member. The filing appropriately reports indirect ownership through 5AM Ventures VII, VI and Opportunities II and includes the required signature and date. The disclosures are consistent with typical venture-fund-held insider reporting and clarify that Schwab disclaims direct beneficial ownership except for any pecuniary interest.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Schwab Andrew J.

(Last) (First) (Middle)
C/O 5AM VENTURE MANAGEMENT, LLC
4 EMBARCADERO CENTER, SUITE 3110

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/11/2025 A 2,941,176 A $1.53 2,941,176 I By 5AM Ventures VII, L.P.(1)
Common Stock 2,625,145 I By 5AM Ventures VI, L.P.(2)
Common Stock 302,770 I By 5AM Opportunities II, L.P.(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
2. The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
3. The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. The Reporting Person is a managing member of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II GP. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
/s/ Andrew J. Schwab 09/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Camp4 Therapeutics Corp.

NASDAQ:CAMP

CAMP Rankings

CAMP Latest News

CAMP Latest SEC Filings

CAMP Stock Data

307.14M
42.85M
35.19%
51.76%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE